JULY IS HERE !!!, page-43

First 43 Last

Share
Profile

Follow
Jasper22

2,304 Posts.

514

04/07/24

12:32

Post #: 74605656
Share

Originally posted by Stockman: ↑

Hi Rebekah,
I was around back then (approximately 2014) when the share price spiked to $1.32 in waiting on the results of the study. Yes you are 100% right, the study ended up being a failure due to the flawed design of the study itself. The results of the study drew inconclusive at the time. After a full post mortem, PBT Management recognised where they fell short and set about to change things moving forward. Fast forward 10 years and now we not only have an "open study" in progress but also a "double blinded placebo study". The two biggest differences with each study is 1, the open label study is for long term MSA sufferers and the double blind placebo study is for new MSA Sufferers. The other difference is with the Open Label Study, Scientists can openly talk with the Patients and make adjustments throughout the Study based on each patients progress.
As Outlander2 pointed out a couple of days ago, we may see a difference in results from each study as the iron build up in a long term sufferers will be much greater and take a lot longer to rectify.
Either way, to answer the quote from 5 Cents, I still believe we are on the right track here. I believe we will definitely be successful and I am confident Dr Stamler has already engaged in conversation with potential partnering suitors. Dr Stamler is a sharp guy and a good operator. He has previous experience in taking orphan drugs to market. He certainly knows what it takes and I have all the confidence in the world he will get us over the finish line. One thing to take note of here is, we have so much to look forward to over the next six months leading up to the results of the double blind placebo study next January. Next weeks results aren't the bee all and end all of what ATH is doing, albeit important, we have other fish to fry over the coming 6 months. Giving Dr Stamler 120,000,000 Options is a massive sign we are certainly on the right track and we are going to be successful in due course. Dr Stamler would be looking for the exit doors rather than a big bag full of options if the trials weren't shaping up to be fruitful. Take a moment to let that resonate. This man is on a mission and he knows exactly what he is doing. Personally, I am really excited about the next 6 months and think Alterity may surprise us all.

Stockman

Expand

Hope your right because they've achieved FA in my book with the SP falling like it has

ATH Price at posting: 0.5¢ Sentiment: Hold Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

RXL

Diamond drilling hits gold at 16.71 g/t for Rox at Paddy's Lode, extending mineralisation

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

There are more pages in this discussion • 37 more messages in this thread...

First 43 Last

Add ATH (ASX) to my watchlist

(20min delay)
Last 0.3¢		Change 0.000(0.00%)		Mkt cap ! $15.96M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

Buyers (Bids)

No.	Vol.	Price($)
29	20902248	0.3¢

Sellers (Offers)

Price($)	Vol.	No.
0.4¢	128657356	26

View Market Depth

No.	Vol.	Price($)
29	20902248	0.003
70	90403179	0.002
28	140710099	0.001
0	0	0.000
0	0	0.000

Price($)	Vol.	No.
0.004	128657356	26
0.005	18848455	22
0.006	22089363	18
0.007	53073650	24
0.008	42418463	31

Last trade - 10.39am 04/10/2024 (20 minute delay)

ATH (ASX) Chart

Day chart unavailable

JULY IS HERE !!!, page-43

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Diamond drilling hits gold at 16.71 g/t for Rox at Paddy's Lode, extending mineralisation

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

JULY IS HERE !!!, page-43

Top Stories

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Diamond drilling hits gold at 16.71 g/t for Rox at Paddy's Lode, extending mineralisation

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News